Kalaris Therapeutics/$KLRS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kalaris Therapeutics
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
- Ticker
- $KLRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 20
- Headquarters
- Berkeley Heights, United States
- Website
- kalaristx.com
KLRS Metrics
BasicAdvanced
$45M
-
-$1.91
-
-
Price and volume
Market cap
$45M
52-week high
$11.88
52-week low
$1.78
Average daily volume
81K
Financial strength
Current ratio
10.004
Quick ratio
9.732
Interest coverage (TTM)
-28.75%
Profitability
EBITDA (TTM)
-46.791
Management effectiveness
Return on assets (TTM)
-34.40%
Return on equity (TTM)
-97.23%
Valuation
Price to book
0.95
Price to tangible book (TTM)
0.95
Growth
Earnings per share change (TTM)
-44.73%
What the Analysts think about KLRS
Analyst ratings (Buy, Hold, Sell) for Kalaris Therapeutics stock.
Analyst projections of the future price of Kalaris Therapeutics stock.
KLRS Financial Performance
Revenues and expenses
KLRS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.